Company / Net Income
Matinas BioPharma Holdings, Inc. Net Income History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$24.3M
FY2024
5-year range
-$24.3M / -$21.0M
FY2020-FY2024
Trend
-15.5%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Net Income has fluctuated over the past 10 years, ranging from -$24M in FY2024 to -$8M in FY2016.
Based on SEC 10-K filings.
-$24M in FY2024.
Declined from -$23M to -$24M over the past 2 years.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2024, net income decreased 15.5% year-over-year.
- Peak net income was recorded in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -18.50 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$24.3M | -15.5% |
| FY2023 | -$21.0M | +9.8% |
| FY2022 | -$23.3M | +0.0% |
| FY2021 | -$23.3M | -3.7% |
| FY2020 | -$22.4M | -59.4% |
| FY2019 | -$14.1M | +9.1% |
| FY2018 | -$15.5M | -69.5% |
| FY2017 | -$9.1M | -20.2% |
| FY2016 | -$7.6M | +16.8% |
| FY2015 | -$9.1M | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026